Efficacy of the antinicotinic compound MB327 against soman poisoning - Importance of experimental end point

Toxicol Lett. 2018 Sep 1:293:167-171. doi: 10.1016/j.toxlet.2017.11.006. Epub 2017 Nov 7.

Abstract

Medical countermeasures for acute poisoning by organophosphorus nerve agents are generally assessed over 24h following poisoning and a single administration of treatment. At 24h, the antinicotinic bispyridinium compound MB327 (1,10-(propane-1,3-diyl)bis(4-tert-butylpyridinium)) dimethanesulfonate is as effective as the oxime HI-6 against poisoning by soman, when used as part of a treatment containing atropine and avizafone. In this study, we hypothesised that an earlier endpoint, at 6h, would be more appropriate for the pharmacokinetics and mechanism of action of MB327 and would therefore result in improved protection. MB327 diiodide (33.8mg/kg) or the oxime HI-6 DMS (30mg/kg), in combination with atropine and avizafone (each at 3mg/kg) was administered intramuscularly to guinea pigs 1min following subcutaneous soman and the LD50 of the nerve agent was determined at 6h after poisoning for each treatment. The treatment containing HI-6 gave a similar level of protection at 6h as previously determined at 24h (protection ratios 3.9 and 2.9, respectively). In contrast, the protection achieved by treatment containing MB327 showed a striking increase at 6h (protection ratio >15.4) compared to the 24h end point (protection ratio 2.8). The treatment gave full protection for at least 5h against doses of soman up to 525μg/kg; in contrast, mortality began in animals treated with HI-6 after 1h. This study demonstrates the importance of using an appropriate end point and has shown that treatment including MB327 was far superior to oxime-based treatment for poisoning by soman, when assessed over a pharmacologically-relevant duration. The improved outcome was seen following a single dose of treatment: it is possible that additional doses to maintain therapeutic plasma concentrations would further increase survival time. Antinicotinic compounds therefore offer a promising addition to treatment, particularly for rapidly aging or oxime-insensitive nerve agents.

Keywords: Antinicotinic; Bispyridinium compounds; Guinea-pig; MB327; Nerve agent poisoning; Nicotinic acetylcholine receptor antagonists; Organophosphorus anticholinesterase; Oximes; Soman.

MeSH terms

  • Animals
  • Chemical Warfare Agents / poisoning*
  • Chemical Warfare Agents / toxicity
  • Cholinesterase Inhibitors / pharmacokinetics
  • Cholinesterase Inhibitors / poisoning*
  • Cholinesterase Inhibitors / toxicity
  • Cholinesterase Reactivators / therapeutic use
  • Dose-Response Relationship, Drug
  • Endpoint Determination
  • Guinea Pigs
  • Injections, Intramuscular
  • Lethal Dose 50
  • Nicotinic Antagonists / pharmacokinetics
  • Nicotinic Antagonists / therapeutic use*
  • Organophosphate Poisoning / drug therapy
  • Oximes / therapeutic use
  • Pyridinium Compounds / pharmacokinetics
  • Pyridinium Compounds / therapeutic use*
  • Soman / poisoning*
  • Soman / toxicity
  • Survival Analysis

Substances

  • Chemical Warfare Agents
  • Cholinesterase Inhibitors
  • Cholinesterase Reactivators
  • MB327
  • Nicotinic Antagonists
  • Oximes
  • Pyridinium Compounds
  • Soman
  • asoxime chloride